Feasibility of ECG-Based Glucose Monitoring System

Inclusion Criteria: * Males and females, age 18 years or older. * Subjects can communicate clearly, fully understand the informed consent form, and are aware of the rights and obligations of the study. * Category 1: Subjects without a medical history of hyperglycemia / hypoglycemia or type 1 / type 2 diabetes. Category 2: Subjects having diabetes mellitus (DM) and HbA1c value of. 5.5% to 10%, with eGFR ≥ 60 mL/min. Category 3: Subjects having chronic kidney disease (CKD) and diabetes. mellitus (DM), with eGFR \< 60 mL/min. • Willing and able to participate in all aspects of the study. Exclusion Criteria: * Subjects suffering from insomnia or severe digestive system disorders within 3 months prior to the screening visit. * Subjects who are addicted to alcohol or caffeine. * Existing severe cardiac conditions such as recent myocardial infarction or advanced heart failure within 6 months prior to the screening visit. * Has experienced an episode of confirmed or suspected diabetic ketoacidosis (DKA) within 6 months prior to the screening visit. * Subjects who are vulnerable groups or with higher risks, such as HIV carriers, pregnant women or planning to become pregnant within the study duration, breast-feeding mothers, subjects with rare diseases, physical disabilities, incurable fatal diseases, dependents in nursing homes, incapacity, or intellectual or mental disabilities. * Has a concomitant disease or condition that may compromise subject safety such as unstable coronary heart disease, cystic fibrosis, serious psychiatric disorder, or any other uncontrolled medical conditions. * Any active infection or malignancy requiring acute therapy. * Having coagulation disorders. * Has known allergy to medical adhesives. * Subjects using any cardiac related implantable medical devices such as a pacemaker and so on. * Subjects on certain drugs known to cause arrhythmias or significantly impact kidney function or blood glucose levels (except for the current daily use medication). * Subjects have used defibrillators within 3 months prior to the screening visit. * Currently participating in another device or drug study. * Currently receiving dialysis treatment or planning to receive dialysis during the study. * Any other clinical condition that, in the investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy.